ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,049.88
0.05%
Dow Jones
44,705.53
-0.17%
US Dollar vs MXN
20.3429
-0.34%
Brent Oil
73.535
2.29%
Bitcoin
96,009.40
0.15%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. IO Biotech Inc (IOBT) Cotización

IO Biotech Inc

IO Biotech Inc (IOBT)

NASDAQ
0.8604
-0.0385
(-4.28%)
Al cierre: 03 Diciembre 3:00PM
Delayed by 15 minutes
0.8329
-0.0275
( -3.20% )
Fuera de horario: 3:02PM
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
0.8329
Postura de Compra
0.8329
Postura de Venta
0.90
Volume Operado de la Acción
406,035
0.8104 Rango del Día 0.935108
0.66 Rango de 52 semanas 2.098
Capitalización de Mercado [m]
54.872M
Precio Anterior
0.8989
Precio de Apertura
0.935108
Hora
980
@
0.8329
(formt)
Última hora de negociación
15:02:09
Volumen financiero
US$ 348,348
Precio Promedio Ponderado
0.857925
Volumen promedio (3 m)
565,702
Acciones en circulación
65,880,914
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.64
Beneficio por acción (BPA)
-1.31
turnover
-
Beneficio neto
-86.08M

Acerca de IO Biotech Inc

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced imm... IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.iobiotech.com
Sede
Wilmington, Delaware, USA
Fundado
-
IO Biotech Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IOBT. The last closing price for IO Biotech was US$0.90. Over the last year, IO Biotech shares have traded in a share price range of US$ 0.66 to US$ 2.098.

IO Biotech currently has 65,880,914 shares in issue. The market capitalisation of IO Biotech is US$59.22 million. IO Biotech has a price to earnings ratio (PE ratio) of -0.64.

IOBT Últimas noticias

Más noticias

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

12 Noviembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

12 Noviembre 2024
Edgar (US Regulatory)

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with...

12 Noviembre 2024
GlobeNewswire Inc.

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines...

11 Noviembre 2024
GlobeNewswire Inc.

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda® demonstrated promising activity with an overall response...

07 Noviembre 2024
GlobeNewswire Inc.

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines...

04 Octubre 2024
GlobeNewswire Inc.

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety...

14 Septiembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

30 Agosto 2024
Edgar (US Regulatory)

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety...

30 Agosto 2024
GlobeNewswire Inc.

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...

26 Agosto 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.07299.592105263160.760.950.714307680.84523206CS
4-0.3172-27.58021041651.15011.290.667600370.84048888CS
12-0.077101-8.472628052060.9100011.420.665657020.94323702CS
26-0.3671-30.59166666671.21.730.663668721.0406879CS
52-0.3871-31.72950819671.222.0980.662462471.17998077CS
156-9.0071-91.53556910579.8412.580.661435612.12894698CS
260-15.1671-94.7943751617.880.661438522.40732714CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
HTOOFusion Fuel Green PLC
US$ 0.5253
(66.23%)
1.4M
OKTAOkta Inc
US$ 96.0987
(17.48%)
847k
VIRXViracta Therapeutics Inc
US$ 0.176
(8.11%)
13.49k
NOTVInotiv Inc
US$ 4.49
(7.93%)
6.38k
TCRTAlaunos Therapeutics Inc
US$ 2.5482
(7.43%)
1,000
ORISOriental Rise Holdings Ltd
US$ 9.00
(-18.99%)
186.94k
CTNTCheetah Net Supply Chain Service Inc
US$ 4.2499
(-11.64%)
140.1k
ALTSALT5 Sigma Corporation
US$ 2.58
(-9.47%)
2k
IMTEIntergrated Media Technology Ltd
US$ 1.41
(-8.44%)
25.46k
ARBBARB IOT Group Ltd
US$ 0.531
(-8.42%)
7.1k
BILIBilibili Inc
US$ 19.2301
(0.10%)
2.48M
HTOOFusion Fuel Green PLC
US$ 0.5236
(65.70%)
1.43M
NVDANVIDIA Corporation
US$ 140.11
(-0.10%)
1.08M
OKTAOkta Inc
US$ 96.30
(17.73%)
852.49k
LSCCLattice Semiconductor Corp
US$ 58.28
(-0.06%)
782.68k

IOBT Discussion

Ver más
ZLAZARUS ZLAZARUS 1 semana hace
Ph3 melanoma data for IO102-IO103 remain on track for 1H25 and represents the next key catalyst. At .70 we are trading at cash. With a positive Ph3 melanoma readout we will be trading at $3.00 overnight with a march to $6.00 towards the later half of 2025. In addition, I'm encouraged by the supportive data in additional solid tumors which increases my confidence in the potential for success in the ongoing Ph3 melanoma study.

Also lets remember the IO102-IO103 melanoma study is with Merck's + pembrolizumab Ketruda. If IOBT's IO102-IO103 is approved, it will be a disruptive game changer thus creating an overnight valuation of about 200 million for the company in 2025. Leading into 2026, we could see a valuation conservatively of about $400M. This is my opinion.
👍️0
ZLAZARUS ZLAZARUS 2 semanas hace
Picked up at 20,000 shares @ .88 , I will pick up more when it drops below .73
👍️0
phrocks phrocks 2 semanas hace
Now you're a participant??
👍️0
ZLAZARUS ZLAZARUS 2 semanas hace
Targeting a fill between .70 & .78 Gem here on positive IOB-013/KN-D18 Q1 2025 Phase III results.
👍️0
Rkrocks Rkrocks 2 meses hace
No real volume
👍️0
Rkrocks Rkrocks 2 meses hace
Monk are we finally on the move with this?
👍️0
axelvento axelvento 2 meses hace
O Biotech is developing a cancer vaccine that targets both the tumor and its microenvironment - a pivotal readout is coming in the first half of next year
Founder and CEO Mai-Britt Zocca explains the rationale for this dual focus and walks us through the lead program that targets PD-L1 and IDO, and which has breakthrough therapy designation. A pivotal study in first line metastatic melanoma will read out soon.

https://www.biotechtv.com/post/io-biotech-october-11-2024
👍️0
Monksdream Monksdream 2 meses hace
IOBT under $2


👍️0
glenn1919 glenn1919 2 meses hace
IOBT.................................https://stockcharts.com/h-sc/ui?s=IOBT&p=W&b=5&g=0&id=p86431144783
👍️0
axelvento axelvento 2 meses hace
IOBiotech
is pleased to announce that it will be presenting two posters at the SITC 2024 Annual Meeting.

The first poster presentation contains updated and expanded data from the complete cohort (n=31) from the first line (1L) cohort of patients with PD-L1 high metastatic non-small cell lung cancer (NSCLC) in our Phase 2 basket trial of investigational IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy. The second poster presentation contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1.

We look forward to sharing these exciting data at the meeting which takes place in Houston from November 6-10, 2024. See full details here:

https://investors.iobiotech.com/news-events/news/news-details/2024/IO-Biotech-Announces-Two-Poster-Presentations-at-the-Society-for-Immunotherapy-of-Cancers-SITC-39th-Annual-Meeting/default.aspx
👍️0
glenn1919 glenn1919 3 meses hace
iobt................................https://stockcharts.com/h-sc/ui?s=IOBT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 3 meses hace
IOBT new 52 week low
https://investorshub.advfn.com/uimage/uploads/2024/9/12/fmdniIMG_1694.gif
👍️0
Monksdream Monksdream 3 meses hace
IOBT under $2
👍️0
PonkenPlonken PonkenPlonken 4 meses hace
starting to run into the readout
Lead investigator and advisors that helped BMS in making ipi+nivo the new SOC --- They now work on this. Cancer vaccines back in fashion.
👍️0
PonkenPlonken PonkenPlonken 4 meses hace
Sorry for the late reply, im not yet fully familiar with this platform.
The SOC for advanced melanoma is Ipi + Nivo which is neither very helpful nor very safe. Hence "the bar is hanging low" here.
👍️0
Monksdream Monksdream 4 meses hace
IOBT
👍️0
stock1ace1 stock1ace1 5 meses hace
Standard of care …
👍️0
Monksdream Monksdream 5 meses hace
IOBT under $2
👍️0
ralfito ralfito 6 meses hace
For us dummies, can you define SOC in this context? Thanks.
👍️0
PonkenPlonken PonkenPlonken 6 meses hace
CEO made it pretty clear numerous times at Jefferies IMO
they will become the SOC, not only in advanced melanoma but in all stages.
They also think their platform can be used for non-cancer indications.

2 Birds in the hand and many more in the bush$$$
👍️0
PonkenPlonken PonkenPlonken 6 meses hace
https://www.youtu be.com/watch?v=OvC-86SN9Ao&ab_channel=VJOncology

australian KOL on IOBT

many things pointing at it becoming the SOC one day...
👍️0
axelvento axelvento 6 meses hace
golden cross MA50 MA200
👍️0
axelvento axelvento 7 meses hace
a planned interim analysis of ORR will be conducted when the first 225 randomized patients reach one year of treatment in June 2024. The outcome of this analysis is expected in the third quarter of 2024 and, if supportive, we believe could allow for submission of a BLA for accelerated approval in the US.
Cash and cash equivalents as of March 31, 2024 were $118.0 million, compared to $143.2 million at December 31, 2023. During the three months ended March 31, 2024, the company used cash, cash equivalents and restricted cash of $24.9 million. The increase in cash use was primarily driven by milestone payments and payment of other accrued expenses associated with clinical trials, as well as the payment of year-end bonuses. The company continues to expect that it will have sufficient cash to run the company into the fourth quarter of 2025.
👍️0
axelvento axelvento 7 meses hace
Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committee
Progressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumors
Ended 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into the fourth quarter of 2025

https://www.biopharmcatalyst.com/company/IOBT/news/190095
👍️0
axelvento axelvento 7 meses hace
https://investors.iobiotech.com/news-events/news/news-details/2024/IO-Biotech-Announces-Abstract-Accepted-for-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting/default.aspx
👍️0
axelvento axelvento 8 meses hace
IO Biotech was founded in 2014 and just 10 years into the journey we are in a pivotal phase III trial I think that’s quite fast
👍️0
axelvento axelvento 8 meses hace
next catalyst-In November 2023, the company completed enrollment of 380 patients in its pivotal Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in advanced melanoma. The primary endpoint of the pivotal Phase 3 trial is progression free survival (PFS). The PFS analysis is event-driven and will be conducted when 226 events have occurred in the trial, which the company estimates will take place in the second half of 2025. Additionally, a planned interim analysis of overall response rate (ORR) will be conducted when the first 225 randomized patients reach one year of treatment in June 2024. The outcome of this analysis is expected in the third quarter of 2024.
👍️0
Monksdream Monksdream 9 meses hace
IOBT under $2
👍️0
Monksdream Monksdream 9 meses hace
IOBT under $2
👍️0
Monksdream Monksdream 1 año hace
IOBT new 52 week low
👍️0
Monksdream Monksdream 1 año hace
IOBT new 52 week low
👍️0
Monksdream Monksdream 1 año hace
IOBT ubder $2
👍️0
AJ Freely AJ Freely 1 año hace
$IOBT - 👆Up 1.8% Pre-Market/ Current Price $2.00
Announces $75 Million Private Placement Financing
👍️0
The Night Stalker The Night Stalker 1 año hace
nice
👍️0
kzivann kzivann 1 año hace
Extremely heavy volume on good news. PPS down . Lower this AM. Watching

IOBT
👍️0
Phosphene Phosphene 3 años hace
IO Biotech’s (NASDAQ:IOBT ) lock-up period is set to end on Wednesday, May 4th.

https://www.defenseworld.net/2022/04/27/io-biotech-inc-s-lock-up-period-set-to-end-on-may-4th-nasdaqiobt.html
👍️0
conix conix 3 años hace
Bitoechs are waking up ---like they did last year.

I shopped for a number of sold out biotechs in December and picked and chose a number of sold out biotechs.

IOBT --I missed. But there are legs here. I have done well on four of my picks. Still waiting on two.

Time will tell.
👍️0
Phosphene Phosphene 3 años hace
IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for treating multiple tumor types

https://www.globenewswire.com/news-release/2021/12/06/2346557/0/en/IO-Biotech-Announces-Third-Clinical-Collaboration-with-Merck-to-Evaluate-IO102-IO103-in-Combination-With-KEYTRUDA-pembrolizumab-as-First-Line-Treatment-in-a-Phase-2-Multi-Arm-Baske.html

👍️0
Eggplant Eggplant 3 años hace
What happened? IPO at $14/sh four weeks ago, and the stock has nearly folded in half. No news, and the only sellers should be the IPO buyers, right? Mystery.
👍️0
Work Harder Work Harder 3 años hace
I was right on the 7

for now

Yu tell wifeie

I appreciate her time

:}
👍️0
Phosphene Phosphene 3 años hace
Did Sunstone/Verland recoup initial seed?









👍️0
Staypositive1 Staypositive1 3 años hace
might wait till .035...lol
👍️0
Phosphene Phosphene 3 años hace
IO Biotech begins trading on Nasdaq Global Market today.

IPO pps is $14.

Thu, November 4, 2021, 11:52 PM.

https://finance.yahoo.com/news/io-biotech-inc-announces-pricing-035200314.html?fr=sycsrp_catchall

Sunstone and Novo Holdings involved.
👍️0
Phosphene Phosphene 3 años hace
EXPLORATORY PROJECT TO COMPARE IO BIOTECH ANTIGENS LINKED TO MYMETICS’ (MYMX) VIROSOMES IN A PRECLINICAL TUMOR MODEL

https://www.mymetics.com/media-center/exploratory-project-compare-io-biotech-antigens-linked-mymetics-virosomes-preclinical-tumor-model/


IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

https://www.prnewswire.com/news-releases/io-biotech-announces-clinical-collaboration-with-msd-to-evaluate-io102-io103-with-keytruda-pembrolizumab-as-first-line-treatment-in-metastatic-melanoma-patients-in-a-phase-3-trial-301375679.html
👍️0
Phosphene Phosphene 3 años hace
Denmark's IO Biotech seeks $110M+ in Nasdaq debut.

https://pitchbook.com/newsletter/denmarks-io-biotech-seeks-110m-in-nasdaq-debut

https://www.fiercebiotech.com/biotech/io-biotech-raises-155m-to-trial-ido-and-pd-l1-cancer-vaccines

https://www.iobiotech.com/

The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/ metastatic melanoma

https://www.firstwordpharma.com/node/1783725?tsid=17
👍️0

Su Consulta Reciente

NASDAQ
IOBT
IO Biotech
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados